Active cooperation among APAC pharma companies gaining traction: GlobalData
According to GlobalData’s Pharmaceutical Intelligence Center, from 2019 to 2023, 673 deals (strategic alliances) occurred among…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pharmaceutical Intelligence
India pharma giants and global big pharma join forces for NMEs commercialisation in India:…
The focus is on introducing new molecular entities (NMEs) into India, with both parties contributing to accelerate…
India’s fight against rare diseases needs more focus on awareness and diagnosis: GlobalData
In November 2023, the Indian Union Health Ministry authorised the sale of four generic medications for the treatment of rare…
Investment in novel therapies key priority to tackle AMR: GlobalData
As per GlobalData Pharmaceutical Intelligence Center’s pipeline drugs database, there are around 929 antibiotics and 182…
Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData
GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China
ImmunoACT to lead journey of indigenous CAR-T cell therapy in India but market access a hurdle:…
As per ImmunoACT CEO, NexCAR19 will be available at a price of Rs 30-40 lakh ($36,000- $48,000), which is 1/10th of the cost of…
Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData
Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023
Antibody-drug conjugates gain traction in China oncology market: GlobalData
The diagnosed prevalent cases of gastric, breast, and bladder cancers in China are expected to increase at a CAGR of 2.6 per cent,…
Long road ahead for non-statin therapies in Australia dyslipidemia treatment space: GlobalData
According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in…
Licensing agreement deals decline in rare diseases space: GlobalData
Big pharma companies are searching for innovative biotechs to invest in the rare diseases space